U.S., March 19 -- ClinicalTrials.gov registry received information related to the study (NCT07479732) titled 'Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma' on March 06.
Brief Summary: In advanced osteosarcoma where traditional chemotherapy has failed, the multi-targeted tyrosine kinase inhibitor apatinib has become a mainstream systemic treatment option in China. However, for patients with a high tumor burden or extra-pulmonary lesions, these drugs are prone to secondary resistance, necessitating combination with chemotherapy for more effective comprehensive control. Liposomal irinotecan, a newly approved topoisomerase inhibitor, exhibits lower toxicity compared to traditional irinotecan and is one ...